19.08
+0.35(+1.87%)
Currency In USD
Address
5 Science Park
New Haven, CT 06511
United States of America
Phone
203 535 1456
Website
Sector
Healthcare
Industry
Biotechnology
Employees
445
First IPO Date
September 27, 2018
| Name | Title | Pay | Year Born |
| Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer & President | 1.14M | 1960 |
| Dr. Ian Taylor Ph.D. | President of Research & Development and Chairman of Scientific Advisory Board | 732,256 | 1962 |
| Ms. Angela M. Cacace Ph.D. | Chief Scientific Officer | 0 | 1968 |
| Mr. Andrew R. Saik | Chief Financial Officer & Treasurer | 0 | 1969 |
| Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary | 0 | 1969 |
| Dr. Randy Teel Ph.D. | Chief Business Officer | 0 | 1980 |
| Mr. Steve Weiss | Senior Vice President & Chief Human Resources Officer | 0 | 1970 |
| Mr. John P. Northcott | Chief Commercial Officer | 0 | 1978 |
| Mr. Paul McInulty | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Ms. Lisa Sinclair | Senior Vice President of Corporate Operations | 0 | N/A |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.